Clinical studies have shown that EGCG can reduce ALT, TG, and atherosclerotic lipoprotein levels, which lowers the incidence of cardiovascular disease associated with NAFLD [56]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.